Journal profile · Peripheral Vascular Disease
Arteriosclerosis Thrombosis and Vascular Biology
ISSN 1079-5642 · eISSN 1524-4636 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Monthly · Founded 1995
Arteriosclerosis Thrombosis and Vascular Biology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 8.73; hybrid open access; median 116 days to acceptance (30 articles, last 24 months); community-reported acceptance: fairly hard; 541 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Arteriosclerosis Thrombosis and Vascular Biology is published by Lippincott Williams and Wilkins Ltd. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Atherosclerosis and Cardiovascular Diseases, Lipoproteins and Cardiovascular Health and Angiogenesis and VEGF in Cancer, together about 25.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Leading basic, translational, clinical, and population research related to arteriosclerosis, thrombosis, and vascular biology
From the journal's Aims & Scope
Research area (LetPub): Peripheral Vascular Disease
Editor-in-chief Ann Marie SchmidtPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology12.5%
- Lipoproteins and Cardiovascular HealthMedicine6.6%
- Angiogenesis and VEGF in CancerBiochemistry, Genetics and Molecular Biology6.5%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine5.4%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine5%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology4.6%
- Nitric Oxide and Endothelin EffectsMedicine4.5%
- Cholesterol and Lipid MetabolismMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
| Minor | Peripheral Vascular Disease | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
| Minor | Peripheral Vascular Disease | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 2 |
| Minor | Peripheral Vascular Disease | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 8.73LetPub ·
- CiteScore 2026-06
- 12.2LetPub ·
- SJR 2026-06
- 2.88LetPub ·
- SNIP 2026-06
- 1.93LetPub ·
- h-index
- 251LetPub ·
- h-index
- 342OpenAlex ·
- i10-index
- 9,504OpenAlex ·
- 2-year mean citedness
- 3.01OpenAlex ·
- Self-citation rate
- 2.3%LetPub ·
- Share of gold OA articles
- 24.66%LetPub ·
Volume
- Articles per year
- 193LetPub ·
Articles by year OpenAlex count · 19,966 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 558 | 116 | 137 |
| 2025 | 541 | 137 | 1,302 |
| 2024 | 668 | 181 | 3,884 |
| 2023 | 692 | 211 | 5,056 |
| 2022 | 511 | 166 | 5,233 |
| 2021 | 423 | 232 | 8,193 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
116 daysMedian, submission to acceptance · P25–P75 66 days – 177 days
- Acceptance to online
- median 17 days (30 articles)
- Submission to online
- median 138 days
- Sample
- 30 articles with submission and acceptance dates (1,180 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 2–4 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1995
- ISSN
- 1079-5642
- Electronic ISSN
- 1524-4636
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Arteriosclerosis Thrombosis and Vascular Biology
What CAS zone is Arteriosclerosis Thrombosis and Vascular Biology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Arteriosclerosis Thrombosis and Vascular Biology is in Zone 1 of Medicine, and in Zone 2 of the minor category Hematology / Peripheral Vascular Disease; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Arteriosclerosis Thrombosis and Vascular Biology?
The latest impact factor listed by LetPub is 8.73; CiteScore 12.2, h-index 342.
How long does peer review take at Arteriosclerosis Thrombosis and Vascular Biology?
Based on the dates recorded on 30 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 116 days (interquartile range 66–177 days); authors report an average review time of 2–4 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Arteriosclerosis Thrombosis and Vascular Biology?
According to LetPub and DOAJ records, Arteriosclerosis Thrombosis and Vascular Biology is indexed in SCIE and Scopus.
Is Arteriosclerosis Thrombosis and Vascular Biology open access, and what is the APC?
Arteriosclerosis Thrombosis and Vascular Biology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .